Stock Research: Jubilant Life Sciences

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Jubilant Life Sciences

BSE:530019 INE700A01033
57
  • Value
    17
  • Growth
    73
  • Safety
    Safety
    53
  • Combined
    44
  • Sentiment
    46
  • 360° View
    360° View
    57
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Jubilant Pharmova Limited is an India-based integrated pharmaceutical company. It operates in Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, and Proprietary Novel Drugs. The company operates in India. In the last fiscal year, the company had a market cap of $2201 million, profits of $575 million, and revenue of $847 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 57 (better than 57% compared with alternatives), overall professional sentiment and financial characteristics for the stock Jubilant Life Sciences are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Jubilant Life Sciences. The consolidated Value Rank has an attractive rank of 53, which means that the share price of Jubilant Life Sciences is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 53% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 73, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 46. Professional investors are more confident in 54% other stocks. Worryingly, the company has risky financing, with a Safety rank of 17. This means 83% of comparable companies have a safer financing structure than Jubilant Life Sciences. ...read more

more
Index
SDG 13
SDG 14
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 10-Sep-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
53 55 83 81
Growth
73 77 25 1
Safety
Safety
17 21 37 31
Sentiment
46 67 34 16
360° View
360° View
57 65 34 7
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
57 97 93 89
Opinions Change
50 50 50 50
Pro Holdings
n/a 60 21 4
Market Pulse
55 38 11 17
Sentiment
46 67 34 16
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
53 55 83 81
Growth
73 77 25 1
Safety Safety
17 21 37 31
Combined
44 49 45 13
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
53 36 69 89
Price vs. Earnings (P/E)
71 71 91 89
Price vs. Book (P/B)
62 67 90 84
Dividend Yield
22 29 61 28
Value
53 55 83 81
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
75 48 27 14
Profit Growth
8 98 8 6
Capital Growth
80 17 63 29
Stock Returns
83 99 65 7
Growth
73 77 25 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
23 16 22 22
Refinancing
43 66 90 88
Liquidity
23 18 16 22
Safety Safety
17 21 37 31

Similar Stocks

Discover high‑ranked alternatives to Jubilant Life Sciences and broaden your portfolio horizons.

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

NMDC

BSE:526371
Country: India
Industry: Steel
Size: Medium
Full Stock Analysis

Maruti Suzuki

NSEI:MARUTI
Country: India
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.